4.36Open4.36Pre Close0 Volume11 Open Interest5.00Strike Price0.00Turnover1057.99%IV-41.59%PremiumJan 17, 2025Expiry Date4.55Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7619Delta0.4365Gamma0.10Leverage Ratio-0.0128Theta-0.0007Rho-0.07Eff Leverage0.0002Vega
Relmada Therapeutics Stock Discussion
Dow Jones· 5 mins ago
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint With Statistical Significance
No comment yet